You are here
- Home
- Therapy Areas
- Oncology/Infection
(NCIC CTG) A phase two study of ZD6474 in patients with relapsed multiple myeloma
- Disease
- solid tumour
- Drug Name
- Caprelsa
- Generic Name
- vandetanib
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- II
- Start Date
- May 31, 2002
- Study Name
- 6474IL/0002
- Study Id
- 6474IL/0002
- ClinicalTrials.gov ID
- NCT00034918
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
